Extrait

This will be a double-blind, placebo controlled cross-over study. After enrolment and initial assessments, subjects will receive oral SB681323 or matching placebo for 14 days. SB681323 will be administered twice daily at a total daily dose of 7.5mg. Sufficient numbers of patients will be recruited to obtain 40 evaluable patients

Critère d'inclusion

• Pain, Neuropathic ,neuropathic pain ,Nerve Trauma

Liens

• ictrp
• nct